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Relationships among natriuresis, atrial natriuretic peptide and insulin
in insulin-dependent diabetes. Insulin-dependent diabetic patients have a
large exchangeable body sodium pooi, secondary to sodium retention.
The pathogenesis of impaired natriuresis in insulin dependent diabetes
remains to be elucidated. The present study examines the role of
hyperinsulinemia, impaired atrial natriuretic release, and resistance to
atrial natriuretic peptide action in determining sodium retention in
normotensive and hypertensive insulin-dependent diabetic patients.
Eight insulin-dependent diabetic patients had significantly higher daily
sodium excretion rate (147 16 mmol/day; mean SE) during conven-
tional insulin treatment (daily plasma glucose: 11.6 1.2 mmol/liter;
daily plasma insulin: 27 3 .tU/ml) than during intensified insulin
treatment (daily sodium excretion rate: 91 12, P <0.01; daily plasma
glucose: 6.8 0.7, P < 0.01; daily plasma insulin: 44 4, P < 0.01).
Daily sodium excretion rate was also significantly lower (107 13, P <
0.01) in the same diabetic patients during intensified insulin treatment
along with hyperglycemic clamp (daily plasma glucose: 12.8 0.3, NS;
plasma insulin 48 4, P < 0.01). Seven control subjects had lower
extracellular liquid volume than eight insulin-dependent diabetic pa-
tients (11.0 0.8 1/1.73 m2 vs. 14.8 0.9, P < 0.05) and also had
baseline plasma atrial natriuretic peptide concentrations (18 5 pg/mI
vs. 37 4, P < 0.05). Atrial natriuretic peptide response to saline
challenge was blunted in insulin-dependent diabetic patients when
saline was administered on the basis of body surface area (90 nimol/l.73
m2 . 90 mm) but not when administered on the basis of extracellular
liquid volume (ECV) (8.2 mmol/liter ECV 90 mm). Continuous infu-
sion of atrial natriuretic peptide in the same control and diabetic
subjects (0.06 rg/kg mm . 120 mm) resulted in similar circulating
concentrations of the hormone but in significantly lower sodium excre-
tion rate in diabetic (from 185 19 to 193 21 smol/f .73 m2 mm) than
in control subjects (199 14 to 341 22, P < 0.01). Natriuretic action
of atrial natriuretic peptide was similarly impaired in a group of eighteen
hypertensive insulin-dependent diabetic patients in comparison with a
matched group of seven hypertensive control patients. Angiotensin
converting enzyme inhibitor treatment in these hypertensive diabetic
patients decreased extracellular liquid volume and improved natriuretic
response to atrial natnuretic peptide. We conclude that refractoriness to
natriuretic action rather than impaired release of atrial natriuretic peptide
can further deteriorate sodium retention in insulin dependent diabetes.
This altered hormonal behavior could be primarily due to insulin-induced
sodium retention and extracellular liquid volume expansion.
A large exchangeable body sodium pool has been reported in
normotensive [1—3] and hypertensive [4] IDDM patients who
are without evidence of renal or vascular complications. Ex-
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changeable body sodium pool is further increased in IDDM
patients with established nephropathy (defined as albumin
excretion of greater than 500 mg/24 hr) [5] and also in those with
microalbuminuria or incipient nephropathy (defined as albumin
excretion rate between 30 and 500 mg/24 hr) [6].
The increased exchangeable mass of sodium is accompanied
by a concomitant increase in the ECV [6, 7] and of plasma
volume [81, although this latter finding has not been uniformly
confirmed [4, 6]. An expansion in sodium exchangeable mass
has been frequently advocated to explain the frequent associa-
tion between hypertension and IDDM [9]. However, it has to be
pointed out that some studies have also reported that the
prevalence of hypertension in IDDM is similar to that showed
by a non-diabetic population [10]. From a hemodynamic point
of view, a larger plasma volume and an expanded ECV could
lead to increased cardiac output and in turn to increased blood
pressure levels and glomerular filtration rate. This cascade of
events should be eventually able to buffer the expansion in the
magnitude of ECV [11, 121. According to this hypothesis, the
expansion in plasma volume is an early and transient phenom-
enon which is rapidly overcome by the cardiovascular feedback
system to maintain a stable hemodynamic condition in all
tissues [11, 12], and it is therefore missed if plasma volume is
evaluated when this hemodynamic rearrangement has already
occurred.
Whatever the relationship between plasma and ECV, IDDM
patients have impaired natriuretic response to volume expan-
sion either induced by head-out water immersion [5, 13, 14] or
by saline infusion [3]. The pathogenesis of this impaired capac-
ity of handling a sodium load in IDDM is unclear. The present
study examines the role of insulin and ANP in determining
sodium retention in IDDM.
Methods
Patients
Twenty-six type I, insulin-dependent diabetic (IDDM) pa-
tients with onset of the disease before the age of 30, aged 17 to
42 years, were divided into two groups: normotensives (N = 8)
with blood pressure levels below 140 and 85 mm Hg and
hypertensives (N 18) with blood pressure levels above 145
and 90 mm Hg, for systolic and diastolic values, respectively,
813
814 Fioretto et al: ANP and insulin-dependent diabetes
according to the statement on Hypertension in Diabetes Melli-
tus [15]. Seven non-diabetic hypertensive patients and seven
normotensive healthy subjects were selected from those attend-
ing the outpatient clinic of the Internal Medicine Department,
University of Padova. A complete medical workup was per-
formed to rule out the diagnosis of secondary hypertension.
Kidney, liver and endocrine (except for IDDM) function was
normal. An additional criterion for inclusion in the study was
the presence of normal body weight (<15% above or below
desirable body weight) [163. IDDM patients with duration of
diabetes higher than 11 years were not included. Patients with
neovascularization and fibroproliferation on standard eye ex-
amination, or with autonomic neuropathy, were also not taken
into consideration. All IDDM patients were taking two or three
daily subcutaneous insulin injections. Only patients who
showed HbAIC values lower than 7.5% in the 12 months
preceding the study were included. In the six months preceding
the study, each patient was visited at least twice a month by one
of the physicians involved in the study. Major efforts were
dedicated to improve the degree of metabolic control. Each
patient was admitted to the hospital one week before the study.
Eight out of the eighteen hypertensive IDDM patients were on
antihypertensive therapy: five on beta-blockers, two on calcium
antagonists and one on angiotensin converting enzyme inhibi-
tors. Hypertensive IDDM patients on antihypertensive treat-
ment had sodium excretion rates not significantly different from
those of patients who were without previous treatment during
the week of admission in the ward. Any antihypertensive
therapy was discontinued one week before hospital admission
and during hospital stay, and subjects followed an isocaloric
diet containing 50% carbohydrate, 25% fat, and 25% protein.
The daily intake of NaCl was 100 mmol/day during the week
preceding each study. All control and IDDM subjects were
considered to be in sodium balance in the three days preceding
each study on the basis of sodium intake and sodium excretion
rate values. The estimated sodium intake before hospital ad-
mission was 100 to 150 mmol/day without significant differences
between control and IDDM subjects. Plasma ct-eatinine concen-
tration was normal in all IDDM and control subjects. All
subjects and patients had sterile urine and normal urine micros-
copy. The level of albumin excretion rate was determined as the
median value of three 24-hour urine collections, free of ketone
bodies within a fortnight. Control subjects and norniotensive
diabetic patients had an albumin excretion rate lower than 20
g/min; 6 out of the 18 hypertensive diabetic patients had an
albumin excretion rate higher than 20 g/min and lower than 36
g/min (Table 1). All subjects gave informed consent and the
experimental design was approved by the local Ethical Com-
mittee of the University of Padova.
Procedures
Study 1: Effects of hyperinsulineinia. Normotensive IDDM
patients were studied thrice: A) during conventional insulin
regimen, with two daily injections of soluble (Actrapid HM,
Novo, Rome, Italy) and long acting (Protophane HM, Novo)
insulin preparations before breakfast and dinner (0.5 U/kg/day);
B) during intensified insulin regimen with three daily injections
of soluble insulin before breakfast, lunch and snack, and with
one evening injection of soluble and long-acting insulin prepa-
ration before dinner (0.7 U/kg/day); C) during intensified insulin
Table 1. Clinical features of normotensive (NC) and hypertensive
(HC) control subjects normotensive (NP-IDDM) and hypertensive
(HP-IDDM) insulin-dependent diabetic patients
Diabetic patients
Control subjects (NP- (HP-
NC HC IDDM) IDDM)
Number and gender 4M/3F 3M/4F 5M/3F 1OMI8F
Body mass index 23.9 1.0 24.0 1.1 22.9 0.7 23.6 0.8
kg/rn2
Age years 33 2 32 2 31 3 39 4
Duration of diabetes — — 10 3 16 4
years
Blood pressure S 122 5 160 6 119 4 152 8
levels mm Hg D 77 3 95 5 76 2 97 3
Plasma renin activity 1.7 0.2 1.9 0,3 0.8 0.2 0.9 0.3
ng/ml/hr
Plasma creatinine 88 7 95 7 80 8 107 II
pmo1Iliter
Albumin excretion 5 (3—10) 12 (4—25) 8 (6—12) 18 (7—36)
rate g/min
Values are expressed as mean SE or as median with range.
Abbreviations are: S, systolic; D, diastolic.
regimen as described in (B), but with variable amounts of
glucose infusion in order to clamp blood glucose concentrations
at hyperglycemic levels (between 10 and 20 mmol/liter), using a
Beckman glucose analyzer to determine blood glucose concen-
tration with a glucose-oxidase technique (Beckman, Milano,
Italy) every fifteen minutes, and a Harvard continuous infusion
pump (Harvard, Apparatus, Boston, Massachusetts, USA).
Other details have been provided elsewhere [17]. Intermittent
blood samples were withdrawn every 60 minutes to measure
plasma glucose and free insulin concentrations. Twenty-four-
hour urines were collected to determine daily sodium excretion
rate. During protocol, an overnight fasting blood sample was
taken for measurement of plasma renin and creatinine concen-
tration.
Study 2: Atrial natriuretic peptide response to isotonic vol-
ume expansion. Normotensive IDDM patients and control
subjects received a single intravenous injection of 3.7 MEq
51chromium edetic acid (51Cr EDTA) after an overnight fast at
euglycemic levels achieved in IDDM patients by a subcutane-
ous overnight continuous infusion of insulin (Actrapid HM 15
mU/kg. hr with a bolus MC 20 insulin-infusion device; Miles,
Ames, Cavenago, Milan, Italy) in order to measure ECV. Blood
samples for tracer determination were drawn before and 1, 2, 3,
4, 5, 7, 10, 12.5, 15, 30, 45, 60, 90, 120, 150, 180, 210, 250, 300,
330, 360, 420 minutes after the bolus intravenous injection of
5tCr EDTA. The time-course decay of tracer concentration
followed a two exponential equation fit [181. Both IDDM
patients and control subjects received an intravenous infusion
of 90 mmol/1.73 m2 90 mm (154 mM) (Saline I). Normotensive
IDDM patients received an intravenous infusion of saline in a
second occasion following the same procedures, except for the
fact that saline load was administered of the basis of ECV, that
is, 8.2 mmollliter of ECV equal to that used in normotensive
control subjects (that is, 8.2 mmol/liter of ECV) (Saline II). This
latter saline load, however, was greater than that used in normal
control subjects, when expressed as mmol/l .73 m2 body surface
area (121 vs. 90 mmol/l.73 m2), as IDDM patients had similar
body surface area but larger ECV. Renal hemodynamics,
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hormonal parameters and sodium excretion rate were evaluated
as described elsewhere [3, 19—21].
Study 3: Responsiveness to atrial natriuretic peptide. Renal
and systemic responses to atrial natriuretic peptide (ANP)
infusion were studied in seven normotensive and seven hyper-
tensive non-diabetic patients, and eight normotensive and eigh-
teen hypertensive diabetic patients. In addition the eighteen
hypertensive diabetic patients were also studied in a second
occasion after three months of treatment with angiotensin
converting enzyme inhibitor (Cilazapril, Ro 31-2848, F. Hoff-
mann-La Roche Co. Ltd., Basel, Switzerland). All subjects
were studied in the morning after an overnight fast in a
recumbent position. Intravenous catheters were placed bilater-
ally for administration of ANP and blood sampling, respec-
tively. Urine samples were obtained by free voiding at timed
intervals. After a stabilization period of 30 to 60 minutes
following intravenous catheter placement, all individuals re-
ceived an oral water load of 500 ml. Renal plasma flow and
glomerular filtration rate were determined as previously de-
scribed during Study 2. After completion of the 120-minute
equilibration period, there were three 30-minute phases of urine
collection at baseline, and four 30-minute phases of urine
collection during the ANP constant infusion at a rate of 0.06
tgIkg. mm 120 mm, preceded by a priming dose of 10 and 15
sg ANP bolus intravenous injection in non-diabetic and IDDM
subjects, respectively. Urine output was replaced on a milliliter
per milliliter basis throughout the study by administering oral
water. All infusion were given by a constant-rate infusion
pump, with the final concentration of ANP adjusted for pa-
tient's body weight. The administered volume during the exper-
imental infusion period was 50 ml/l.73 m2 120 mm. Equal
volumes of 0.9% sodium chloride were given during the base-
line phase for each individual. Heart rate and cuff blood
pressure were recorded at 10 minute intervals, throughout the
study. Upon completion of lead-in stabilization and each of the
urine collection periods, blood samples were obtained for
'251-para-aminohippurate ('251-PAH) and 51Cr-EDTA radioac-
tivity (dpm/ml). Serum electrolytes, hematocrit, serum protein
(albumin and total) and plasma inimunoreactive (ir) ANP were
obtained upon completion of lead-in stabilization and each of
the urine collection periods. Urine collections were obtained at
time 0 and at the end of each collection period for volume,
'251.PAH and 51Cr-EDTA radioactivity (dpm/ml), and sodium.
Plasma glucose, insulin, atrial natriuretic peptide, hemoglobin
A1, electrolyte and protein concentrations were measured as
described in detail elsewhere [3, 19—21], as well as glomerular
filtration rate, renal plasma flow, sodium excretion and albumin
excretion rate [3, 19—21]. Standard parametric and non-para-
metric statistical analysis was used to assess the degree of
significant differences [3, 19—211.
Results
Effects of hyperinsulinemia with euglycemia (Study 1)
IDDM patients, during conventional insulin treatment, had a
daily mean value of plasma glucose of 11.5 1.3 (mmol/liter)
and plasma insulin of 27 3 (jiU/ml). During intensified insulin
regimen with strict metabolic control plasma glucose concen-
tration decreased to 6.3 0.8 (mmol/liter; P < 0.01) and plasma
insulin concentration rose to 44 4 (U/ml; P < 0.01). During
intensified insulin regimen along with hyperglycemic glucose
clamp plasma glucose concentration was between 12.5 and 15.0
mmol/Iiter throughout most of the day, whereas plasma insulin
concentration was not significantly different from that found
during intensified insulin regimen (48 4 tU/m1) with strict
metabolic control without additional glucose administration.
Daily sodium excretion rate was 147 16 mmol/24 hr during
conventional insulin regimen (Fig. IA) and decreased to 91 12
mmol/24 hr (P < 0.01) during intensified insulin regimen with
strict metabolic control (Fig. 1B) and to 107 13 mmol/24 hr (P
<0.01) during the intensified insulin regimen along with hyper-
glycemic glucose clamp (Fig. IC). Daily sodium excretion rate
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during intensified insulin regimen with strict metabolic control
was slightly but significantly lower than that during intensified
insulin regimen along with hyperglycemic glucose clamp (Fig. 1
B vs. C, P < 0.05).
ANP response to isotonic volume expansion (Study 2)
ECV was larger in IDDM patients (14.8 0.9 1/1.73 m2) than
in control subjects (11.0 0.8 1/1.73 m2, P < 0.05). Baseline
ANP plasma values were significantly higher in IDDM patients
(37 4 pg/mi) than in control subjects (18 5 pg/mi, P <0.05).
Isotonic volume expansion (saline I: 90 mmol/l.73 m2 90 mm;
such as, 6.1 mmolIl ECV . 90 mm) raised ANP plasma values to
a peak concentration of 39 7 pg/mi (P < 0.01 vs. baseline) in
control subjects but not in IDDM patients (44 6 pg/mi, NS vs.
baseline). After the saline I load, sodium excretion rate in-
creased significantly from 125 21 mo1/min 1.73 m2 to 355
30 smol/min. 1.73 m2 (P < 0.01) in control subjects and from
130 25 mol/min 1.73 m2 to 207 35 tmol/min/1.73 m2 (P <
0.05) in IDDM. Saline II volume expansion raised significantly
ANP plasma values from a baseline steady state concentration
of 33 6 to a peak value of 56 8 pg/ml (P < 0.01) in IDDM
patients. Sodium excretion rate went from 120 31 tmol/
mm 1.73 m2 to 269 43 mol/min. 1.73 m2.
Responsiveness to ANP (Study 3)
ANP administration resulted in similar circulating concentra-
tions of the hormone (291 35 vs. 302 39 pg/mI), but resulted
in significantly higher sodium excretion rates in normotensive
controls (from 199 14 to 340 22 jsmol/min 1.73 m2, P <
0.01) than in normotensive IDDM patients (from 185 19 to 193
21 mol/min 1.73 m2, NS; Fig. 2). ANP raised significantly
hematocrit and plasma protein values in normotensive control
subjects but not in hypertensive IDDM patients (Fig, 2). Mean
blood pressure fell and glomerular filtration rate was raised both
in normotensive control and normotensive IDDM patients,
albeit this hormonal action of ANP was more marked in
controls than in IDDM patients (Fig. 2). Filtration fraction (FF)
was increased significantly in normotensive IDDM patients but
not in normotensive control subjects (Fig. 2). A resistance to
the action of ANP was shown also in hypertensive IDDM
patients in comparison with hypertensive control patients with
regard to sodium excretion rate, hematocrit, mean blood pres-
sure and glomeruiar filtration rate (Fig. 3).
Effects of angiorensin converting enzyme (ACE) inhibition in
hypertensive IDDM patients (Study 4)
Three months of treatment with Cilazapril, an ACE inhibitor,
significantly decreased blood pressure levels, albumin excretion
rate, and baseline ANP concentration (Table 2). No change was
found in GFR, whereas RPF was significantly increased. Daily
sodium excretion rate increased significantly from 94 14
(mmol/24 hr) to a peak value of 142 18 (mmol/24 hr; P < 0.01)
in the first month of ACE inhibitor treatment (Fig. 4). On
average IDDM patients had an overall loss of 679 66 mmoi
during the 3 month antihypertensive treatment. Thereafter daily
sodium excretion rate went down to the rate shown by hyper-
tensive TDDM patients before ACE therapy (Fig. 4). The
natriuretic response to ANP challenge was improved by ACE
inhibitor treatment to patterns close to those of hypertensive
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Fig. 2. Mean SE and individual values of sodium excretion rate,
hematocrit, plasma proteins, mean blood pressure, glomerular filtra-
lion rate (GFR) and filtration fraction (FF) in normotensive controls
and IDDM patients at baseline and during ANP continuous infusion.
NS, not significant; P values are Base vs. ANP.
controls (from 177 39 to 533 42 imol/min . 1.73 m2, P <
0.01; Fig. 5). Cilazapril treatment also resulted in a significant
decrease in the magnitude of ECV of hypertensive IDDM
patients (from 15.98 0.46 to 12.00 0.45 liter/1.73 m2, P <
0.01), A positive significant correlation was found between
baseline ANP plasma concentrations and ECV, taking into
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Table 2. Data are mean SE and median with range values of blood
pressure levels, albumin excretion rate, baseline ANP concentration,
glomerular filtration rate and renal plasma flow in hypertensive
IDDM patients before and after Cilazapril treatment
Ace inhibitor treatment
(Cilazapril)
Before After
Blood pressure S 152 8 137 5"
levels mm Hg D 97 3 84 3"
Albumin excretion rate ag/min 18 (7—36) 10 (4—19)"
Glomerular filtration rate 128 7 125 8
mi/mm 1.73 m2
Renal plasma flow mi/mm 1.73 m2 637 33 661 22
Baseline ANP concentration pg/mI 38 5 23
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Fig. 4. Mean SE daily sodium excretion rate in hypertensive IDDM
patients at baseline during placebo and during 3 month ACE inhibitor
(Cilazapril, Roche) treatment. < 0.05 Cilazapril vs. Placebo.
tion of these studies is that insulin administration showed an
antinatriuretic action, mainly after acute administration with
plasma hormone concentrations, higher than those found in
normal subjects. Moreover, the subjects who participated in
most of these studies followed a diet containing a supplemen-
tation of sodium chloride [26, 29]. Little information is available
in humans on the sodium retentive effect of insulin after more
prolonged administration which results in hormone concentra-
tions closer to physiological levels during diets having a normal
sodium intake.
With regard to insulin-dependent diabetes, it has to be
pointed out that sodium excretion rate is heavily influenced by
the circulating levels of glucose [30] as well as of ketone bodies,
lactate and other intermediate compounds [19—21, 31, 32],
which are often altered in diabetic patients with poor metabolic
control with low plasma insulin levels. Therefore, to elucidate
the role of insulin on sodium retention in IDDM, the sodium
NS
Base ANP
P< 0.01
Base ANP
Fig. 3. Mean SE and individual values of sodium excretion rate,
hematocrit, mean blood pressure and giomerular filtration rate (GFR)
in hypertensive controls and IDDM patients at baseline and during
ANP continuous infusion. NS, not significant; P values are Base vs. ANP.
consideration all the values shown by IDDM patients before
and after Cilazapril treatment (r:0.79; P < 0.01).
Discussion
Insulin-induced sodium retention
Numerous in vitro and in vivo studies have documented that
changes in plasma insulin concentration are capable of altering
electrolyte transport in the kidney [22—29]. However, a limita-
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excretion rate has to be investigated during hormone adminis-
tration, resulting in similar insulin circulating concentrations
both at hyperglycemic and euglycemic levels.
The present study demonstrates that daily sodium excretion
rate is lower in euglycemic and slightly hyperinsulinemic than in
hyperglycemic underinsulinized IDDM patients during a diet
with normal sodium intake. Hyperinsulinemia itself, irrespec-
tive of or in addition to hyperglycemia, seems responsible for
the increased transport of sodium from intratubular space to
circulation, as the sodium excretion rate was significantly lower
in hyperglycemic and hyperinsulinemic diabetic patients, sug-
gesting that hyperglycemia is not capable of counterbalancing
the action of insulin in renal sodium handling.
Plasma hyperinsulinemia is almost unavoidable during sub-
cutaneous insulin therapy in IDDM, since higher circulating
levels of this hormone are needed to achieve and maintain
euglycemia for peripheral rather than intraportal insulin admin-
istration [17] and for insulin resistance [33]. Hyperinsulinemia,
in turn, determines sodium retention and expansion of ECV. A
common feature of the syndromes characterized by salt and
fluid retention is the development of hormonal abnormalities in
the attempt to protect the cardiovascular system from an
excessive circulating volume overload [34]. In IDDM, for
instance, insulin-induced sodium retention is accompanied by
lower renin and aldosterone and by higher angiotensin II and
norepinephrine plasma concentration, an endocrine reassess-
ment aiming to raise kidney sodium excretion even by increas-
ing blood pressure levels.
Thus one should predict that sodium retention and an expan-
sion in ECV in IDDM leads to increased cardiac release of ANP
[35]. ANP is indeed elevated in a subgroup of patients with
essential hypertension who have low renin concentrations, a
hormonal behavior resembling that of IDDM patients [36].
ANP release
The present study confirms previous findings of our labora-
tory [31 that euglycemic well-insulinized IDDM patients have
higher baseline plasma concentrations of ANP. The most plau-
sible mechanism accounting for this hormonal abnormality is a
chronic stimulation of cardiac release into circulation of ANP,
by intra- and extravascular volume expansion secondary to
insulin-induced sodium retention. Our results are in keeping
with those of the majority [3, 14, 37—40], but not all [2, 13, 41],
of the previous reports on this matter. These discrepancies
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Fig. 5. Mean SE plasma atrial natriuretic
peptide (ANP) concentration in hypertensive
IDDM patients during placebo (L — — — L) and
after 3 months of Cilazapril (•— •) treatment
at baseline and during ANF infusion (top
panel). Mean SE sodium excretion rate in
300 the same patients during placebo (0) and after
Cilazapril () **D < 0.01 Cilazapril vs.
placebo.
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concerning the patterns of ANP in IDDM could be due to the
following reasons. First, central blood volume, rather than
intravascular volume per Se, is a determinant of ANP release.
Therefore it can be postulated that ANP can be normalized
whenever IDDM patients are capable of reassessing a hormonal
milieu to keep a constant circulating blood volume, despite
insulin-induced extracellular volume expansion. Second, most
of the above-cited studies were performed in poorly-controlled
IDDM patients, in whom glycosuria could have caused marked
sodiuria and dehydration. Trevisan et al [42] recently showed
that hyperglycemia can paradoxically ameliorate the abnormal-
ities, both in ANP release and action, shown by IDDM patients
at euglycemic levels.
With regard to ANP release in response to different stimuli,
we previously found impaired ANP release during saline-
induced isotonic volume expansion [3]. On the contrary, normal
circulating ANP response has been found after head-out of
water immersion in IDDM patients [5, 14]. These findings are
only apparently in disagreement, as one has to bear in mind that
IDDM patients had larger ECV. Therefore it is likely that
head-down-tilt or head-out of water immersion causes a more
potent redistribution of intravascular fluid volume from the
periphery to the thoracic space in IDDM than in non-diabetic
subjects, which in turn results in normal or even higher ANP
release. On the contrary, saline infusion is not able to ade-
quately stimulate ANP in IDDM patients, since saline load is
excessively diluted in the larger ECV, which leads to impaired
distension of atrial myocytes. When saline challenge is admin-
istered on the basis of the magnitude of ECV instead of body
weight, ANP response to isotonic volume expansion was com-
parable in IDDM and control subjects. However, the sodium
excretion rate was always significantly lower in IDDM than in
normal subjects, whatever the infused saline load, even when
the release of ANP was comparable in controls and IDDM
patients. This latter finding raises the hypothesis that resistance
to, rather than impaired release of ANP, plays a pivotal role in
determining sodium retention in IDDM.
Resistance to ANP
The results of the present study demonstrate that the action
of ANP is blunted both in normotensive and in hypertensive
IDDM patients at euglycemic levels.
These findings are in agreement with the observation of
Jungman et al [43] that in normotensive IDDM patients there is
evidence for a decreased responsiveness to ANP with regard to
excretion of renal fluids, sodium and chloride. In addition, we
found that the hormonal action of ANP on kidney hemodynam-
ics, blood pressure levels and other parameters of fluid reten-
tion, such as hematocrit and plasma proteins, was impaired in
IDDM in comparison with normal subjects. At variance with
the above-cited reports and with our findings, normal effects of
ANP on systemic and renal hemodynamics and renal excretory
function in IDDM was shown by other authors [41, 441.
Although further studies are needed to elucidate this issue, it
has to be pointed out that some of these latter investigations
were performed in hyperglycemic IDDM patients [41], in
whom, as suggested by Trevisan et al [42], the natriuretic action
of ANP could have been enhanced by hyperglycemia.
With regard to the mechanisms explaining the blunted sys-
temic and renal response to ANP in IDDM, it is interesting that
other pathologic states characterized by chronic sodium reten-
tion and ECV expansion, such as congestive heart failure [37]
and experimental nephrosis [45], have been reported to have
higher circulating levels and attenuated responses to ANP
administration. The mechanisms underlying the abnormal renal
response to ANP in IDDM are open to speculation. Among the
possible hypotheses, an altered sensitivity of ANP receptors
can be considered as a consequence of a decreased receptor
number and/or affinity, secondary to down-regulation by ele-
vated plasma ANP concentration. This hypothesis, however,
appears unlikely, since it has been reported that rats with
experimental nephrosis, in which ANP plasma concentrations
are also chronically elevated, have normal ANP receptor affin-
ity and density in renal inner and outer medulla [45].
Alternatively, the possibility can be considered that insulin
can blunt the effects of ANP at the kidney level, As a matter of
fact ANP action is due to a stimulation of GFR [35], to
inhibition of Na/H antiport activity in the inner medullary
collecting duct cells [46], and to inhibition of Na/H antiport
in proximal tubular brush border membrane [47]. This latter
mechanism is not due to the binding of ANP with specific
receptors, which are missing at this kidney level, but is likely to
be mediated by ANP-induced dopamine inhibition of Na-H
antiport [47]. Insulin increases sodium reabsorption by renal
proximal [3, 22] and distal tubules [25, 28], and generally
increases NaH antiport activity [48].
The present study, however, provides convincing indirect
evidence that the resistance to ANP action in IDDM is, to some
extent, related to insulin-induced sodium retention via a chronic
stimulation of ANP cardiac release by the expansion of ECV,
which in turn down-regulates the hormone receptor density.
The treatment with the angiotensin converting enzyme inhibi-
tor, Cilazapril, was associated with a significant increase of
sodium excretion rate in the first weeks of drug administration
and with a decrease in the ECV at the end of the treatment. The
overall loss of sodium pool magnitude during antihypertensive
treatment was 679 mmol. This figure is roughly comparable to
that calculated on the basis of the decrease in ECV (—4 liters)
assuming a sodium concentration of 145 m, such as 580 mM.
The difference could be accounted for by slight changes in
sodium intake after the dismissal from the ward. It is interesting
to highlight that we observed similar results using diuretic
therapy (data not shown), which decreases sodium pool by
completely different mechanisms from ACE inhibitors. More-
over, a significant inverse correlation was found between
plasma ANP baseline concentration and ECV. Interestingly,
this decrease in baseline levels of ANP, was also accompanied
by higher natriuretic response to hormone infusion, although
the circulating levels of insulin did not change. These findings
suggest that Cilazapril inhibits the chronic stimulation of ANP
release, mainly by ameliorating sodium homeostasis, and that
this effect is associated with an improved hormone action in
vivo.
Whatever the mechanism accounting for the refractoriness to
the renal and hemoconcentrating effects of ANP infusion in
patients with IDDM, where endogenous plasma hormone re-
lease is chronically stimulated by insulin-induced expansion of
ECY, a decreased responsiveness to, rather than an impaired
cardiac release of ANP, plays a major role in the pathogenesis
of sodium and water retention in IDDM and can further
820 Fioretto et a!: ANP and insulin-dependent diabetes
deteriorate the untoward effects of insulin therapy on sodium
homeostasis.
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